Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis.
Brodalumab
Psoriasis
Psoriatic arthritis
QoL
Ustekinumab
Journal
Dermatology (Basel, Switzerland)
ISSN: 1421-9832
Titre abrégé: Dermatology
Pays: Switzerland
ID NLM: 9203244
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
07
2021
accepted:
18
10
2021
pubmed:
26
11
2021
medline:
9
7
2022
entrez:
25
11
2021
Statut:
ppublish
Résumé
Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with psoriasis that significantly impairs physical function and quality of life (QoL). Prompt therapeutic intervention is crucial for limiting PsA progression and preventing disability. The aim of this study was to compare the efficacy of brodalumab versus ustekin-umab and the impact on QoL in patients with moderate-to-severe plaque psoriasis, by concomitant PsA status. This post hoc analysis of pooled data from the phase 3 AMAGINE-2 and -3 trials evaluated complete skin clearance (100% improvement of Psoriasis Area and Severity Index [PASI 100]), improvement in symptom severity (Psoriasis Symptom Inventory [PSI] response), and QoL (Dermatology Life Quality Index [DLQI] score of 0/1) by concomitant PsA status. A competing risk model assessed cumulative incidence over 52 weeks with outcomes of PASI 100 or inadequate response. This analysis included 929 patients with moderate-to-severe psoriasis. Concomitant PsA was present in 79/339 (23%) and 110/590 (19%) patients receiving brodalumab 210 mg and ustekinumab, respectively. At Week 52, odds ratios (ORs) (95% confidence intervals [CIs]) for complete clearance with brodalumab versus ustekin-umab were 3.15 (1.52-6.55, p = 0.0015) in patients with concomitant PsA and 3.05 (2.19-4.26, p < 0.0001) in patients without concomitant PsA. Corresponding Week 52 ORs (95% CIs) for DLQI 0/1 with brodalumab versus ustekinumab were 2.05 (1.07-3.90, p = 0.0277) and 1.83 (1.32-2.53, p = 0.0002); Week 52 ORs (95% CIs) for PSI ≤8 with brodalumab versus ustekinumab were 3.42 (1.43-8.18, p = 0.0036) and 1.40 (1.01-1.95, p = 0.0434). The 52-week cumulative incidence of patients achieving PASI 100 was significantly higher for brodalumab versus ustekinumab in patients with concomitant PsA (p = 0.0001) and in those without concomitant PsA (p < 0.0001). Treatment with brodalumab rapidly results in high levels of complete and sustained skin clearance and greater cumulative treatment benefit in patients with moderate-to-severe psoriasis versus ustekinumab, regardless of concomitant PsA status.
Sections du résumé
BACKGROUND
BACKGROUND
Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with psoriasis that significantly impairs physical function and quality of life (QoL). Prompt therapeutic intervention is crucial for limiting PsA progression and preventing disability.
OBJECTIVES
OBJECTIVE
The aim of this study was to compare the efficacy of brodalumab versus ustekin-umab and the impact on QoL in patients with moderate-to-severe plaque psoriasis, by concomitant PsA status.
METHODS
METHODS
This post hoc analysis of pooled data from the phase 3 AMAGINE-2 and -3 trials evaluated complete skin clearance (100% improvement of Psoriasis Area and Severity Index [PASI 100]), improvement in symptom severity (Psoriasis Symptom Inventory [PSI] response), and QoL (Dermatology Life Quality Index [DLQI] score of 0/1) by concomitant PsA status. A competing risk model assessed cumulative incidence over 52 weeks with outcomes of PASI 100 or inadequate response.
RESULTS
RESULTS
This analysis included 929 patients with moderate-to-severe psoriasis. Concomitant PsA was present in 79/339 (23%) and 110/590 (19%) patients receiving brodalumab 210 mg and ustekinumab, respectively. At Week 52, odds ratios (ORs) (95% confidence intervals [CIs]) for complete clearance with brodalumab versus ustekin-umab were 3.15 (1.52-6.55, p = 0.0015) in patients with concomitant PsA and 3.05 (2.19-4.26, p < 0.0001) in patients without concomitant PsA. Corresponding Week 52 ORs (95% CIs) for DLQI 0/1 with brodalumab versus ustekinumab were 2.05 (1.07-3.90, p = 0.0277) and 1.83 (1.32-2.53, p = 0.0002); Week 52 ORs (95% CIs) for PSI ≤8 with brodalumab versus ustekinumab were 3.42 (1.43-8.18, p = 0.0036) and 1.40 (1.01-1.95, p = 0.0434). The 52-week cumulative incidence of patients achieving PASI 100 was significantly higher for brodalumab versus ustekinumab in patients with concomitant PsA (p = 0.0001) and in those without concomitant PsA (p < 0.0001).
CONCLUSIONS
CONCLUSIONS
Treatment with brodalumab rapidly results in high levels of complete and sustained skin clearance and greater cumulative treatment benefit in patients with moderate-to-severe psoriasis versus ustekinumab, regardless of concomitant PsA status.
Identifiants
pubmed: 34823247
pii: 000520290
doi: 10.1159/000520290
pmc: PMC9393840
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
brodalumab
6ZA31Y954Z
Ustekinumab
FU77B4U5Z0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
620-629Informations de copyright
The Author(s). Published by S. Karger AG, Basel.
Références
J Eur Acad Dermatol Venereol. 2009 Sep;23 Suppl 1:3-8
pubmed: 19686379
Ther Adv Chronic Dis. 2018 Jan;9(1):5-21
pubmed: 29344327
Clin Rheumatol. 2018 Jul;37(7):1739-1741
pubmed: 29644570
J Dermatolog Treat. 2015 Apr;26(2):103-12
pubmed: 24547907
J Dermatolog Treat. 2017 May;28(3):200-205
pubmed: 27541729
J Rheumatol Suppl. 2020 Jun;96:41-45
pubmed: 32482767
Lancet. 2020 Apr 4;395(10230):1115-1125
pubmed: 32178765
Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii14-7
pubmed: 15708927
Ann Rheum Dis. 2014 Jun;73(6):990-9
pubmed: 24482301
Arthritis Rheumatol. 2016 May;68(5):1060-71
pubmed: 26749174
J Dermatolog Treat. 2015 Jun;26(3):235-9
pubmed: 25078334
F1000Res. 2019 Sep 20;8:
pubmed: 31583079
Expert Rev Clin Immunol. 2018 May;14(5):405-417
pubmed: 29681202
J Autoimmun. 2017 Jan;76:21-37
pubmed: 27836567
Br J Dermatol. 2018 Jul;179(1):173-181
pubmed: 29328510
Dermatology. 2008;216(3):260-70
pubmed: 18187944
J Dermatolog Treat. 2016;27(3):224-7
pubmed: 26447179
Clin Rheumatol. 2018 Feb;37(2):297-305
pubmed: 29134513
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
Dermatologica. 1978;157(4):238-44
pubmed: 357213
Am J Clin Dermatol. 2017 Feb;18(1):147-158
pubmed: 28138946
Dermatol Ther (Heidelb). 2020 Oct;10(5):1099-1109
pubmed: 32761560
Lancet. 2013 Aug 31;382(9894):780-9
pubmed: 23769296
Arthritis Res Ther. 2020 Aug 18;22(1):192
pubmed: 32811543
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):450-457
pubmed: 32662540
J Dermatolog Treat. 2010 Jan;21(1):6-12
pubmed: 19579071
Lancet. 2021 Feb 20;397(10275):754-766
pubmed: 33515492
Clin Rev Allergy Immunol. 2018 Dec;55(3):271-294
pubmed: 28748366
J Am Acad Dermatol. 2020 May;82(5):1138-1149
pubmed: 31884091
N Engl J Med. 2015 Oct;373(14):1318-28
pubmed: 26422722
J Am Acad Dermatol. 2013 Nov;69(5):729-735
pubmed: 23981683
J Immunol. 2014 Apr 15;192(8):3828-36
pubmed: 24646743
J Am Acad Dermatol. 2014 Oct;71(4):633-41
pubmed: 24928705
Drugs R D. 2017 Dec;17(4):509-522
pubmed: 29058302
Arch Med Sci. 2019 May;15(3):580-589
pubmed: 31110522
Ann Rheum Dis. 2015 Jun;74(6):1045-50
pubmed: 24525911
Lancet. 2020 Apr 4;395(10230):1126-1136
pubmed: 32178766
Ann Rheum Dis. 2021 Feb;80(2):185-193
pubmed: 33106286
Nat Rev Rheumatol. 2019 Aug;15(8):461-474
pubmed: 31292564
J Dermatolog Treat. 2013 Oct;24(5):356-60
pubmed: 23092173
N Engl J Med. 2014 Jun 12;370(24):2295-306
pubmed: 24918373